PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
May 30, 2026Chonnam Medical JournalOpen Access

A Cross-Sectional Study on Oral Anticoagulant Utilization and Adverse Drug Reactions at Teaching Hospital, Iran

View Full Paper
Ask AI
Bookmark
Share

Population

1,027 patients aged ≥18 years receiving warfarin, rivaroxaban, or apixaban, mean age 64±16.4 years, 52.3%…

Design

Cross-sectional

Key result

Among patients receiving oral anticoagulants, adverse effects occurred in 12.1% of patients, and guideline-based dosing was achieved in only 61.9% of apixaban and 58.6% of rivaroxaban users.

Authors

SJShima JafariSFSara FarooghiMMMandana Moradi

Discussion

Loading...

Member takes

Overview

Suboptimal dosing adherence warrants clinician review; leaves open whether interventions enhance outcomes in larger cohorts.

Key Points

  • To evaluate the utilization patterns and adverse effects of oral anticoagulants in a hospital setting.
  • Retrospective cross-sectional study conducted from April 2020 to September 2022
  • Data collected from medical records and pharmacy databases for patients receiving warfarin, rivaroxaban, or apixaban
  • Dosing appropriateness assessed using EHRA and UpToDate guidelines, and adverse effects classified according to ACC criteria.
  • Among 1,027 patients, rivaroxaban was most prescribed (43.5%), followed by warfarin (33.2%) and apixaban (23.3%)
  • Adverse effects occurred in 12.1% of patients, mainly minor bleeding, primarily associated with warfarin
  • Guideline adherence for dosing was 61.9% for apixaban, 58.6% for rivaroxaban, and 46.9% for warfarin.

Study Design

Type

Cross-Sectional (n=1,027)

Multicenter

No

Structured PICO

P
Population
1,027 patients aged ≥18 years receiving warfarin, rivaroxaban, or apixaban, mean age 64±16.4 years, 52.3% male, at a tertiary hospital in Iran.
I
Intervention
Oral anticoagulants (warfarin, rivaroxaban, apixaban)
O
Outcome
Utilization patterns, dosing appropriateness, and adverse effectssafety

Guideline adherence for oral anticoagulant dosing was suboptimal, highlighting the need for improved prescriber education and routine renal monitoring.

Limitations

  • Retrospective cross-sectional design relying on medical record review, which may have introduced documentation bias
  • Conducted at a single tertiary care hospital, restricting generalizability
  • Lack of pre-hospital admission information regarding anticoagulant therapy

Cite This Study

Jafari et al. (2026) conducted a cross-sectional in Thromboembolic disorders (n=1,027). Oral anticoagulants (rivaroxaban, warfarin, apixaban) was evaluated on Adverse effects occurrence. Among patients receiving oral anticoagulants, adverse effects occurred in 12.1% of patients, and guideline-based dosing was achieved in only 61.9% of apixaban and 58.6% of rivaroxaban users.

synapsesocial.com/papers/6a1a80550307b7850943244chttps://doi.org/10.4068/cmj.2026.62.2.47
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A Single Health System Retrospective Qualitative Analysis of Inpatient Apixaban and Rivaroxaban Calibrated Anti-Xa Level Monitoring and Clinical Implications2025 · 1 citations
  2. 2Comparative Analysis of Newer Oral Anticoagulants in the Management of Coronary Artery Disease: Safety and Efficacy in an Intensive Care Setting2025
  3. 32188-P: Clinical Benefits and Risks of Reduced-Dose vs. Standard-Dose Direct Oral Anticoagulants in Patients with Atrial Fibrillation: An Observational Analysis of Veterans Affairs Data2026
  4. 4From prescription to outcome: real-world utilization of direct oral anticoagulants in atrial fibrillation across Europe2026
  5. 5Evaluation of the treatment patterns among commercially insured patients with nonvalvular atrial fibrillation prescribed an oral anticoagulant by race/ethnicity2025